renal microvascular responses, we generated several unique p66 Shc mutant rat strains based on the genetic background of Dahl salt-sensitive (SS) rats using CompoZrÒ ZFNs targeting exon 2 of the Shc1 gene. The juxtamedullary vasculature was isolated from these genetically modi- fied rats and afferent arteriolar responses to vasoactive compounds were monitored by videomicroscopy. We have demonstrated that p66 Shc knockout restores vasoconstrictor responses to ATP and increased perfu- sion pressure, which are impaired in SS rats. In patch clamp electrophys- iology experiments carried out with primary smooth muscle cells (SMC) isolated from renal vessels of p66 Shc rat knockouts we established that p66 Shc deficiency results in a dramatic increase in TRPC channels activ- ity in response to Endothelin-1 (ET-1). Correspondingly, ET-1-mediated cytosolic Ca2+ mobilization and activation of [Ca2+]i-dependent cyto- plasmic tyrosine kinase Pyk2 were also increased in SMC derived from p66 Shc knockout rats, when compared with SMC derived from their WT littermates. Moreover, p66 Shc knockout promoted cellular contrac- tility in primary rat SMC. Our data suggest that p66 Shc restrains activity of TRPC channels, attenuating changes in cytosolic Ca2+ concentration, contributing to reduction of autoregulatory responses of juxtamedullary afferent arterioles. These results establish a role for the adaptor protein p66 Shc in the regulation of renal vascular tone and promotion of renal vascular dysfunction. Keywords: Endothelin-1; salt-sensitive hypertension; preglomerular arte- rioles; smooth muscle cells P-181 Relevance of serum phosphorus changes on renal prognosis in patients with essential hypertension Julian Segura , 1 Enrique Morales, 1 Sara Santana, 1 Cesar Cerezo, 1 Lucia Guerrero, 1 Luisa Fernandez, 1 Juan Jose de la Cruz, 2 Manuel Praga, 1 Luis M. Ruilope. 1 1 Hospital 12 de Octubre, Madrid, Spain; 2 Universidad Autonoma de Madrid, Madrid, Spain The relationship between plasma phosphorus and cardiovascular disease has been well described, specially in the presence of chronic kidney dis- ease. This relationship is not as documented in patients with preserved renal function. Recently, some studies have not confirmed this relationship between plasma phosphorus and renal and cardiovascular prognosis. More- over, urinary albumin excretion is considered as an early marker of with the cardiovascular risk. Our aim was to analyze whether changes in plasma phosphorus (P) were associated with renal prognosis in a cohort of patients with essential hypertension. 1361 patients with essential hypertension, 50.2% male, age 60.512.3 years, usually followed at our center, were analyzed. All were followed for a minimun of three years. We classified the patients in two groups, defined by the presence of renal event (development of albuminuria 30 mg/g or progression of albuminuria during follow-up ) or absence of renal event ( maintenance of albuminuria <30 mg/g during the follow-up). Changes in plasma phosphorus (DP) were assessed absolutely (final P - initial P) and relative ( (final P - initial P)/(initial P) x100). At baseline the mean serum creatinine was 1.00.4 mg/dl, estimated glomerular filtration rate (eGFR) using the formula CKD-Epi was 78.425.1 ml/min/1.73m2, and mean plasma phosphorus was 3.30.5 mg/dl. Patients with renal event (n¼363, 26.7%) were older (64.211.5 vs 59.212.3 years), higher systolic blood pressure (14420 vs 13618 mmHg), higher requirements of antihypertensives drugs (2.71.2 vs 2.11.2), higher serum creatinine (1.180.51 vs 0.930.27 mg/dl) and lower eGFR (71.132.7 vs 81.121.1 ml/min/1.73m2) (p<0.001 for all comparisons). Serum phosphorus showed no significant difference (3.290.56 vs 3.280.52 mg/dl). Mean absolute DP was 0.110.55 mg/dl in patients with renal event and 0.060.50 mg/dl in patients without renal event (p¼0.083). Mean relative DP was 4.9 % among patients with renal event and 2.9% among patients without event (p¼0.048). The logistic regression analysis showed that in- dependent factors for the occurrence of renal event were age (odds ratio [OR] 1.029, confidence interval 95% [CI95] 1.017-1.042, p¼0.000), female sex (OR 0.575, CI95 0.432-0.765, p¼0.000), baseline serum creat- inine (OR 4.308 , CI95 2.841-6.533, p¼0.000), diabetes (OR 2.153, CI95 1.652-2.805, p¼0.000) and relative DP (OR 1.009, CI95 1.001-1.017, p¼0.021). In conclusion, in a cohort of essential hypertensive patients regularly fol- lowed in our center, changes in plasma phosphorus during follow-up are an independent risk factor for the development or progression of renal disease. Keywords: phosphorus; kidney function; albuminuria P-182 Renal denervation in patients with resistant hypertension in Ukraine first experience 1 year duration Olga Mironova, Oksana Rekovets, Yuriy Sirenko, Yuriy Sokolov, Maksim Sokolov, Aleksandr Sirenko, Anna Dobrokhod, Elena Torbas, Svetlana Kushnir. Institute of Cardiology, Kiev, Ukraine Background: Recently completed controlled trials have shown efficacy and safety of radiofrequency denervation procedures in patients with resis- tant hypertension (AH). Aim: After 1 year first experience renal denervation in patients with resis- tant hypertension in Ukraine Material and methods: We selected 5 patients (2 male, 3 female) for renal denervation who met all requirements of the protocol. 1 patient has dia- betes mellitus II type. The average age of these patients was 57,6 +/- 3,1 years (40-66 years). Mean duration of hypertension in them was 17,8 +/- 1,5 (13-20) years. When they came to the Institute for the clinic the average office blood pressure (BP) was 182,0/104,0  6,6/6,2 mm Hg, HR - 68,84,2 b.p.m. Optimization of therapy in a hospital in these patients led to significant reduction of blood pressure to 156,0/93,02,9/ 3,0 mm Hg. The number of antihypertensive drugs was on average 5 per patient. 24ABPM (24SBP) was 151,44,8 and diastolic (24 DBP) - 82,64,8 mm Hg, 24HR was 65,3 2,7 b.p.m. Results: All patients underwent the procedure of renal denervation. After 7 days RDN office blood pressure decreased in all patient and the average was 138,464,33/73,302,18 mm Hg, HR - 69,44,4 b.p.m. and 24SBP/DBP was 134,74,1/74,02,3 mm Hg, HR was 67,9 1,2 b.p.m. After 30 days RDN office blood pressure was 155,011,8/ 83,34,6 mm Hg, HR - 65,07,7 b.p.m., 24SBP/DBP was 136,696,42/70,813,04 mm Hg, HR - 65,01,1 b.p.m. After 6 month RDN office BP was 172,58,5/86,25,0 mm Hg, HR - 60,52,9 b.p.m. and 24SBP/DBP was 138,54,3/73,32,2 mm Hg, HR - 63,61,4 b.p.m. After 12 month RDN office BP was 155,05,9/85,02,2 mm Hg and 24SBP/DBP was 130,73,3/68,31,5 mm Hg, HR - 68,84,2 b.p.m. Current levels of creatinine clearance calculated by the formula Cockcroft-Haulta, not significantly changed either in one patient. Conclusion: After 1 year renal denervation ambulatory blood pressure control is more effectiveness than office blood pressure for controlling treatment patient. Decreased 24SBP was 20,7 mm Hg. Decreased 24DBP was 14,3 mm Hg. HR was not significant changed. Keywords: renal denervation; resistant arterial hypertension P-183 Renal denervation in resistant hypertension leads to significant improvement in ambulatory daytime systolic blood pressure: a 12- month follow-up audit from a single UK center Fayaz Khan, Kevin Mohee, Kenneth Wong, Jufen Zhang, Michael S. Cunnington, Adam N. Mather, Simon Thackray. Castle Hill Hospital, Hull, United Kingdom Introduction: Hypertension has caused many deaths, strokes and heart failure. Renal sympathetic denervation in resistant hypertension appeared e103 Abstracts / Journal of the American Society of Hypertension 8(4S) (2014) e99–e105